These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1092575)

  • 1. Assessment of the efficacy of influenza vaccines against natural challenge.
    Hobson D
    Dev Biol Stand; 1975; 28():285-94. PubMed ID: 1092575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenge versus natural infection as an index or protection after influenza immunization.
    Donikian MA; McKee J; Greene LC
    Dev Biol Stand; 1977 Jun 1-3; 39():149-54. PubMed ID: 342306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potency of influenza vaccines: mouse protection experiments in correlation to field studies in man.
    Bachmayer H; Liehl E; Schmidt G
    Dev Biol Stand; 1975; 28():336-9. PubMed ID: 1126577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective efficacy of live influenza vaccines. Its assessment in field and experimental conditions.
    Jovanovic D; Georges-Delvaux AM; Delem A
    Dev Biol Stand; 1979; 43():241-5. PubMed ID: 391630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of immunity to influenza using artifical challenge of normal volunteers with influenza virus.
    Couch RB
    Dev Biol Stand; 1975; 28():295-306. PubMed ID: 1126573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
    Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.
    Ryan J; Zoellner Y; Gradl B; Palache B; Medema J
    Vaccine; 2006 Nov; 24(47-48):6812-22. PubMed ID: 17034909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Field trial with human and equine influenza vaccines in children: protection and antibody titres.
    Wesselius-de Casparis A; Masurel N; Kerrebijn KF
    Bull World Health Organ; 1972; 46(2):151-7. PubMed ID: 4555773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of the antiinfluenza A vaccination during epidemics due to A/VIC/3/75 and A/Texas/1/77 viruses.
    Aymard M; Bentejac MC; Larbaigt G; Michaut D; Triau R
    Dev Biol Stand; 1979; 43():231-9. PubMed ID: 520670
    [No Abstract]   [Full Text] [Related]  

  • 10. Universal influenza vaccination and live attenuated influenza vaccination of children.
    Glezen WP
    Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S104-9. PubMed ID: 18820568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influenza vaccination coverage rates in 5 European countries: a population-based cross-sectional analysis of the seasons 02/03, 03/04 and 04/05.
    Müller D; Szucs TD
    Infection; 2007 Oct; 35(5):308-19. PubMed ID: 17885730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Live attenuated influenza vaccine in children.
    Ambrose CS; Walker RE; Connor EM
    Semin Pediatr Infect Dis; 2006 Oct; 17(4):206-12. PubMed ID: 17055372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is routine influenza immunization indicated for people over 65 years of age? An opposing view.
    Frame PS
    J Fam Pract; 1988 Feb; 26(2):215-7. PubMed ID: 3339326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An electroaerosol device for group vaccination against influenza.
    Grinshpun L; Priimägi L; Subi K; Reinet J; Visnapuu L
    Z Erkr Atmungsorgane; 1978 Mar; 150(3):237-8. PubMed ID: 695738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines.
    Tamura S; Tanimoto T; Kurata T
    Jpn J Infect Dis; 2005 Aug; 58(4):195-207. PubMed ID: 16116250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine-preventable influenza disease burden from clinical trials of Vaxigrip - an inactivated split virion influenza vaccine - supports wider vaccine use.
    Arnoux S; Weinberger C; Gessner BD
    Vaccine; 2007 Nov; 25(45):7720-31. PubMed ID: 17920168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-radial-immunodiffusion potency tests of inactivated influenza vaccines for use in man and animals.
    Wood JM; Mumford J; Schild GC; Webster RG; Nicholson KG
    Dev Biol Stand; 1986; 64():169-77. PubMed ID: 3098605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duration of circulating and secretory antibody and cell-mediated immunity following immunization.
    Waldman RH; Ganguly R
    Dev Biol Stand; 1975; 28():273-84. PubMed ID: 1126572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of influenza immunization for inner-city children aged 6 to 23 months.
    Zimmerman RK; Hoberman A; Nowalk MP; Lin CJ; Greenberg DP; Weinberg ST; Bemm CW; Block B
    Am J Prev Med; 2004 Dec; 27(5):397-403. PubMed ID: 15556740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine effectiveness against medically attended, laboratory-confirmed influenza among children aged 6 to 59 months, 2003-2004.
    Shuler CM; Iwamoto M; Bridges CB; Marin M; Neeman R; Gargiullo P; Yoder TA; Keyserling HL; Terebuh PD
    Pediatrics; 2007 Mar; 119(3):e587-95. PubMed ID: 17332179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.